Understanding pseudoprogression: why tumors can swell at first during immune checkpoint therapy

Pseudoprogression describes initial tumor swelling caused by an immune response to checkpoint inhibitors. This can mimic growth on scans, so clinicians combine imaging with clinical signs to avoid misreading results and adjust treatment appropriately in cancer care.

Tumors can pull some pretty tricky stunts, especially when the immune system gets involved. One of the quirkiest is pseudoprogression—the moment immune checkpoint inhibitors make tumors look bigger on scans before they shrink, or before they truly settle down. It’s a confusing phase for clinicians and patients alike, but understanding it is key to making smart treatment choices and avoiding unnecessary alarm.

What is pseudoprogression, exactly?

Think of immunotherapy as a rally, not just a punch. Immune checkpoint inhibitors release the brakes on the immune system, letting T cells and other defenders recognize and attack cancer cells. That battle inside the tumor can bring in a surge of immune cells, inflammatory signals, and swelling. The result? On imaging tests like CT or MRI, the tumor may appear to grow or new lesions might pop up. By traditional criteria, that would scream “progression,” but in the immunotherapy world, it can actually signal a robust immune response in motion.

This swelling isn’t random. It happens when the immune system floods the tumor with inflammatory cells, blood flow increases to the area, and fluid accumulates. All of that can make a mass look larger temporarily. It’s a sign that the body is doing something active—fighting back—rather than a straightforward expansion of cancer.

Why the confusion matters

Imaging has long been our window into how cancer behaves, but immunotherapy threw a wrench into that routine. If clinicians rely solely on tumor size without context, they might prematurely switch therapies, pause treatment, or misinterpret symptoms as disease progression. That’s not just a logistical headache; it can impact patient outcomes and quality of life.

The good news is this: with pseudoprogression, you don’t have to choose between guessing and waiting in the dark. There are practical ways to navigate the uncertainty, combining clinical assessment with imaging findings and, when needed, follow-up scans over a short interval to see how things evolve.

How clinicians approach it in practice

Context is everything. Here are the core ideas that guide decision-making when pseudoprogression might be in play:

• Look at the whole patient, not just the scan. If a patient feels better, has fewer symptoms, and shows stable or improving lab markers, that can be a reason to continue therapy despite a radiographic bump.

• Track patterns over time. A single scan showing temporary growth doesn’t tell the whole story. When a tumor swells yet the patient remains clinically stable or improves, clinicians often await a confirmatory scan to see if the trend reverses.

• Consider the biology. Inflammation is part of the immune response. If inflammation is driving the swelling, especially within sites of known immune activity, that’s a clue that the body is mounting a defense, not that the cancer is advancing unchecked.

• Use specialized response criteria. Traditional response metrics can misclassify responses during immunotherapy. Modified criteria take into account immune-related patterns, helping to avoid premature conclusions about progression.

• Have a shared plan. Open conversations with patients about the possibility of pseudoprogression help manage expectations. When patients understand that initial swelling isn’t necessarily a bad sign, it reduces anxiety and supports adherence to the treatment plan.

Real-world signals that raise or lower the suspicion

Pseudoprogression isn’t a blanket phenomenon; it tends to show up in certain contexts more than others. Here are some practical cues clinicians weigh:

• Time on therapy: Early in treatment, especially within the first few cycles, radiographic changes can be more common. If the patient’s clinical picture is stable or improved, a cautious watchful waiting approach may be reasonable.

• Symptom trajectory: Worsening symptoms aligned with rapid tumor growth might point toward true progression, while stable or improving symptoms amid radiographic growth point toward an inflammatory response.

• Lesion behavior: Sometimes new lesions appear alongside shrinking existing ones. In a conventional frame that would be alarming, but in the immunotherapy frame, mixed responses can still be a good sign.

• Heterogeneous responses: Different tumors or sites can respond differently. A shrinking lesion in one area with growth in another isn’t necessarily a contradiction; it can reflect variable immune penetration or local biology.

What it means for patients and families

Facing cancer treatment is stressful, and ambiguity can amplify that stress. Pseudoprogression adds another layer of complexity, but knowledge is empowering. If you or a loved one is navigating immunotherapy, here are ways to stay engaged and informed:

• Ask about the timeline. “How long would you expect to wait before reassessing the response if the scan looks worse but clinical status is stable?” This helps set expectations and reduces impulsive changes.

• Keep a symptom log. A simple diary of energy levels, pain, appetite, and functional abilities can be a powerful companion to imaging results.

• Seek clarity on the criteria used. In many centers, clinicians apply immune-related response criteria that better capture how tumors behave under immunotherapy. Understanding the framework being used can demystify the process.

• Stay in close contact with the care team. If new or worsening symptoms occur, or if there’s concern about the scan, a quick check-in can prevent misinterpretation.

Beyond the hospital walls: what the science is telling us

The concept of pseudoprogression is a reminder that biology doesn’t always follow neat spreadsheets. Our understanding has evolved with real-world experience and deep dives into how the immune system interacts with cancer. Researchers have shown that while pseudoprogression can happen, it doesn’t negate the benefits of immunotherapy for many patients. In some cases, initial swelling is followed by meaningful tumor shrinkage and meaningful extensions in survival.

This isn’t just abstract science. It translates into practical treatment decisions, trial designs, and patient education. It nudges us toward more nuanced response criteria, more thoughtful imaging schedules, and more patient-centered conversations. It’s a prime example of how medicine increasingly blends biology with psychology, strategy with empathy.

A quick tour of the imaging landscape

For students and professionals who want to visualize how pseudoprogression looks in practice, here are some common imaging patterns:

• Tumor diameter increases by a modest amount across scans, with no new symptoms or a slight improvement in performance status.

• New lesions appear, but existing lesions shrink or stabilize, and the patient feels better.

• Peritumoral edema and inflammatory changes are visible without clear signs of widespread disease progression.

In all cases, radiologists don’t operate in a vacuum. They collaborate with oncologists, pathologists, and the patient’s clinical picture to interpret what the imaging is really telling us.

Practical takeaways for anyone curious about immunotherapy’s quirks

• Pseudoprogression is a real phenomenon, not a diagnostic error. It’s a temporary misread by conventional metrics that can mislabel a healthy immune response as disease progression.

• The best approach blends imaging with clinical judgment. Numbers matter, but so do how a patient feels, moves, and functions day to day.

• Modified criteria help clarify the picture. As the science and practice evolve, clinicians increasingly rely on immune-related response frameworks to guide decisions.

• Communication is essential. When patients understand why a scan might look worse at first, they’re less likely to panic and more likely to stay engaged with their treatment plan.

A little analogy to wrap it up

Imagine your body hosting a busy peacekeeping mission. The street chemists in your immune system—the T cells, the macrophages, the cytokines—are sorting through debris, negotiating with neighbors, and rebuilding damaged tissue. In the middle of all that, the neighborhood might look messier before it gets serene again. Pseudoprogression is that temporary messiness. It’s not a signal that the mission failed; it’s a sign that the peacekeeping effort is in full swing.

Where science goes from here

As immunotherapy becomes more mainstream, our understanding of response patterns continues to sharpen. New imaging techniques, biomarkers, and composite endpoints are being explored to capture the nuance of the immune response more precisely. In practice, this translates to better-informed decisions, fewer unnecessary changes in therapy, and, ideally, better outcomes for patients.

If you’re studying this topic, you’ll notice a consistent thread: the need to view cancer treatment as a dynamic, collaborative process. It’s not just about what a scan shows in a moment; it’s about the trajectory, the patient’s lived experience, and the evolving science that ties it all together. Pseudoprogression is a perfect example of that complexity—a reminder that medicine often lives in the gray, not the black-and-white.

Final thought: stay curious, stay connected

Immunotherapy opens doors to new possibilities, but with those doors comes a different way of looking at progress. Pseudoprogression teaches us to read between the lines, to weigh the whole story, and to trust the team’s judgment when the signs aren’t crystal clear. If you’re exploring this field for study or work, keep an eye on how imaging meets immunology—and how that intersection reshapes patient care into something more nuanced, more attentive, and ultimately more hopeful.